Atossa Therapeutics
ATOS
77 hedge funds and large institutions have $31.2M invested in Atossa Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 17 closing their positions.
643% more call options, than puts
Call options by funds: $765K | Put options by funds: $103K
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
15% more funds holding
Funds holding: 67 → 77 (+10)
0.36% more ownership
Funds ownership: 1.03% → 1.39% (+0.36%)
10% less capital invested
Capital invested by funds: $34.7M → $31.2M (-$3.55M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.51M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.72M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 5 |
Bank of New York Mellon
New York
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$4.01M |
| 2 |
Millennium Management
New York
|
-$1.48M |
| 3 |
Goldman Sachs
New York
|
-$776K |
| 4 |
HF
HRT Financial
New York
|
-$524K |
| 5 |
Morgan Stanley
New York
|
-$456K |
ATOS Hedge Fund Activity: Q2 2024 in Review
77 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2024, worth a combined $31.2M — down 10% from $34.7M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ATOS positions and 17 closed out — a net gain of 11 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $9.51M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $4.01M sold.
- 77 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2024, up from 67 in Q1 2024.
- Funds reported $31.2M of Atossa Therapeutics stock for Q2 2024, down 10% quarter-over-quarter.
- 28 funds opened new Atossa Therapeutics positions in Q2 2024 and 17 closed out, a net change of +11 holders.
- The largest Atossa Therapeutics buyer in Q2 2024 was BlackRock, an estimated $9.51M added.
- The largest Atossa Therapeutics seller in Q2 2024 was Laurion Capital Management, an estimated $4.01M sold.
Based on aggregated 13F filings for Q2 2024.